CYP17A1: IHC Expression in Cancer and Radioligand Target Profile
CYP17A1, cytochrome P450 family 17 subfamily A member 1, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CYP17A1 staining is highest in colorectal cancer (46% of samples positive), thyroid cancer (25% of samples positive) and breast cancer (11% of samples positive). Clinical status: FDA-approved drug (any modality).
Is CYP17A1 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze CYP17A1 freeIs CYP17A1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Medium IHC staining in colorectal cancer, 46% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CYP17A1 IHC staining by cancer type
Protein expression of CYP17A1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 0.24 | Medium | 46% |
| Thyroid Cancer | 0.08 | Low | 25% |
| Breast Cancer | 0.04 | Low | 11% |
| Liver Cancer | 0.03 | Low | 10% |
| Prostate Cancer | 0.03 | Low | 9% |
| Gastric Cancer | 0.03 | Low | 9% |
| Ovarian Cancer | 0.03 | Low | 8% |
| Bladder Cancer | 0.03 | Low | 8% |
Not detected by IHC in: skin cancer, head and neck cancer, lymphoma, melanoma, kidney cancer, neuroendocrine tumors, cervical cancer, lung cancer, pancreatic cancer, testicular cancer, endometrial cancer, glioma.
Is CYP17A1 internalized?
Nuclens has not yet extracted internalization evidence for CYP17A1. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
CYP17A1 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for CYP17A1 yet. Search ClinicalTrials.gov for CYP17A1 trials.
CYP17A1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CYP17A1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CYP17A1 gene essentiality (DepMap)
CRISPR knockout effect across 1242 cancer cell lines: -0.03 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EGFR · FAP · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how CYP17A1 ranks against 15,000 targets for your indication.
Analyze CYP17A1 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.